Enanta falls after Gilead HCV data


Shares of Enanta (ENTA -15.4%) are getting hit hard in morning trading.

Likely behind the move is upbeat data from GILD regarding impressive SVR12 rates from Phase 3 studies of a sofosbuvir/ledipasvir combo in GT1 HCV.

ENTA discovered ABT-450, one of the compounds in ABBV's 3D GT1 HCV regimen.

For more on ENTA/ABBV, see here and here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs